Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer

Jann Mortensen; Liselotte Højgaard

Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer

Translated title of the contribution: Radium-223 treatment of bone metastases from castration-resistant prostate cancer.

Jann Mortensen, Liselotte Højgaard

Department of Clinical Medicine

Abstract

The alpha emitter Radium-223 ((22)3Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symp-toms. Intravenously administered (22)3Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.

Translated title of the contribution	Radium-223 treatment of bone metastases from castration-resistant prostate cancer.
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	176
Issue number	30
Pages (from-to)	1399-1402
Number of pages	4
ISSN	0041-5782
Publication status	Published - 21 Jul 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{b17ff97d15fb4d83810b89119d7eacef,

title = "Radium-223 behandling af knoglemetastaser ved kastrationsrefrakt{\ae}r prostatacancer",

abstract = "The alpha emitter Radium-223 ((22)3Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symp-toms. Intravenously administered (22)3Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.",

author = "Jann Mortensen and Liselotte H{\o}jgaard",

year = "2014",

month = jul,

day = "21",

language = "Dansk",

volume = "176",

pages = "1399--1402",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "30",

}

TY - JOUR

T1 - Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer

AU - Mortensen, Jann

AU - Højgaard, Liselotte

PY - 2014/7/21

Y1 - 2014/7/21

N2 - The alpha emitter Radium-223 ((22)3Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symp-toms. Intravenously administered (22)3Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.

AB - The alpha emitter Radium-223 ((22)3Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symp-toms. Intravenously administered (22)3Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.

M3 - Tidsskriftartikel

C2 - 25292232

SN - 0041-5782

VL - 176

SP - 1399

EP - 1402

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 30

ER -

Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer

Abstract

UN SDGs

Fingerprint

Cite this